Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lee, Soyon ^a,b   Mullin, Rachel ^a   Blazawski, Jon ^a   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; WARFARIN;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ADMINISTRATION; DRUG COST; DRUG INDICATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; LIFE EXPECTANCY; MEDICARE; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; PYRAZOLES; PYRIDONES; STROKE; WARFARIN;

EID: 84867298575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047473     Document Type: Article

References (55)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123: e18-e209.
2. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, et al. (2012); on behalf of the American Heart Association Stroke Council, Council on Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2012 Aug 2. [Epub ahead of print].
3. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, et al. (1999) Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131: 927-34.
4. Agarwal S, Bennett D, Smith DJ, (2010) Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs 10: 37-48.
5. Johnston J, Cluxton R, Heaton P, Guo JJ, Moomaw CJ, et al. (2003) Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 163: 1705-1710.
6. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT, (2000) Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160: 41-46.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870.
9. Atrial Fibrillation Investigators, (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154: 1449-1457.
10. O'Brien CL, Gage BF, (2005) Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293: 699-706.
11. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A, (2000) Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 355: 956-962.
12. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, et al. (2011) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154: 1-11.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B, (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1: 175-179.
16. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, et al. (1998) Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 158: 1513-1521.
17. Stroke Prevention in Atrial Fibrillation Investigators, (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348: 633-638.
18. Stroke Prevention in Atrial Fibrillation Investigators, (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343: 687-691.
19. Hylek EM, Singer DE, (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120: 897-902.
20. Ariesen MJ, Claus SP, Rinkel GJ, Algra A, (2003) Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34: 2060-2065.
21. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, et al. (2002) Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288: 2441-2448.
22. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, et al. (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370: 493-503.
23. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, et al. (1999) Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 319: 958-964.
24. Agency for Healthcare Research and Quality. 2003 Nationwide Inpatient Sample. Healthcare Cost and Utilization Project: Rockville, MD; 2003.
25. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM, (2010) Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 104: 1106-1115.
26. United States Census Bureau. The 2011 statistical abstract. Available at: http://www.census.gov/compendia/statab/cats/births_deaths_marriages_divorces.html. Assessed September 22, 2011.
27. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, et al. (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32: 695-703.
28. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, et al. (1993) Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 24: 796-800.
29. Gage BF, Cardinalli AB, Owens DK, (1996) The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 156: 1829-1836.
30. Tsevat J, Goldman L, Lamas GA, Pfeffer MA, Chapin CC, et al. (1991) Functional status versus utilities in survivors of myocardial infarction. Med Care 29: 1153-1159.
31. Sullivan PW, Ghushchyan V, (2006) Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 26: 410-420.
32. Centers for Medicare & Medicaid Services. 2009 Physician Fee Schedule. Baltimore: Centers for Medicare & Medicaid Services; 2008.
33. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality; 2009. http://hcupnet.ahrg.gov/. Accessed September 28, 2011.
34. United States Department of Labor. Consumer Price Index. Bureau of Labor Statistics website. http://www.bls.gov/cpi/. Accessed September 28, 2011.
35. American Medical Association. CPT Code/Relative Value Search. AMA Coding Online website. https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?_requestid=782991. Accessed September 28, 2011.
36. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, et al. (1996) Utilization of acute care services in the year before and after stoke: A population-based study. Neurology 46: 861-869.
37. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G, (1996) Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 46: 854-860.
38. Matchar DB, Samsa GP (2000) Secondary and Tertiary Prevention of Stroke: Patient Outcomes Research Team (PORT) Final Report-Phase 1. AHRQ publication no. 00-N001. Rockville, MD: Agency for Healthcare Research and Quality.
39. Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ, (2008) Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. Am Heart J 156: 698-705.
40. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, et al. (2001) Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 141: 727-734.
41. Roche Diagnostics. 2009 Anticoagulation monitoring Medicare reimbursement handbook for healthcare professionals. http://www.poc.roche.com/en_US/pdf/44156_Coag2009Handbook_FINAL_APPROVED.pdf. Assessed September 28, 2011.
42. Red Book. Montvale, NJ: Thomson Healthcare; 2009.
43. Rivaroxaban (Xarelto)- a new oral anticoagulant (2011) Med Lett Drugs Ther. 53: 65-67.
44. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, et al (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 8: e1-8.
45. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, et al. (2012) Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e531S-75S.
46. Kamel H, Johnston SC, Easton JD, Kim AS, (2012) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 43: 881-883.
47. Kansal AR, Sorensen SV, Guni R, Robinson P, Pan F, et al. (2012) Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98: 573-578.
48. Pink J, Lane S, Pirmohamed M, Hughes DA, (2011) Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 343: d6333.
49. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, et al. (2011) Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 105: 908-919.
50. Langkilde LK, Bergholdt Asmussen M, Overgaard M, (2012) Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ 15: 695-703.
51. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, et al. (2012) Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. Am J Cardiol May 29. [Epub ahead of print].
52. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
53. Friberg L, Rosenqvist M, Lip GY, (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33: 1500-1510.
54. Baker WL, Cios DA, Sander SD, Coleman CI, (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15: 244-252.
55. Grosse SD, (2008) Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8: 165-178.